- Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
- Day One Announces Two New Appointments to Board of Directors
- Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
- Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
- Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
- Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
- Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
- Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
- Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
More ▼
Key statistics
On Thursday, Day One Biopharmaceuticals Inc (DAWN:NSQ) closed at 15.75, -11.76% below its 52-week high of 17.85, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.86 |
---|---|
High | 16.13 |
Low | 14.64 |
Bid | 15.51 |
Offer | 16.39 |
Previous close | 15.75 |
Average volume | 763.86k |
---|---|
Shares outstanding | 87.38m |
Free float | 70.17m |
P/E (TTM) | -- |
Market cap | 1.30bn USD |
EPS (TTM) | -2.37 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 21:00 BST.
More ▼